EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition

Georgios Schoretsanitis, A Elif Anıl Yağcıoğlu, Can-Jun Ruan, Chin B Eap, Espen Molden, Trino Baptista, Scott R Clark, Emilio Fernandez-Egea, Se Hyun Kim, Hsien-Yuan Lane, Jonathan Leung, Olalla Maroñas Amigo und 12 weitere

Schizophrenia Research · 2024

DOI: 10.1016/j.schres.2023.05.010 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Schizophrenia Research, 2024. Verfasst von Georgios Schoretsanitis und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zürich, Zürich, Switzerland; Division of Psychiatry R…. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During weak induction (from smoking and/or valproate co-prescription), clozapine ultrarapid metabolizers (UMs) need very high daily doses to reach the minimum therapeutic concentration of 350 ng/ml in plasma; clozapine UMs need clozapine doses higher than: 1) 900 mg/day in patients of European/African ancestry, or 2) 600 mg/day in those of Asian ancestry. Published clozapine UMs include 10 males of European/African ancestry, mainly assessed with single concentrations. Five new clozapine UMs (two of European and three of Asian ancestry) with repeated assessments are described. A US double-blind randomized trial included a 32-year-old male smoking two packages/day with a minimum therapeutic dose of 1,591 mg/day from a single TDM during open treatment of 900 mg/day. In a Turkish inpatient study, a 30-year-old male smoker was a possible clozapine UM needing a minimum therapeutic dose of 1,029 mg/day estimated from two trough steady-state concentrations on 600 mg/day. In a Chinese study, three possible clozapine UMs (all male smokers) were identified. The clozapine minimum therapeutic dose estimated with trough steady-state concentrations >150 ng/ml was: 1) 625 mg/day, based on a mean of 20 concentrations in Case 3; 2) 673 mg/day, based on a mean of 4 concentrations in Case 4; and 3) 648 mg/day, based on a mean of 11 concentrations in Case 5. Based on these limited studies, clozapine UMs during weak induction may account for 1-2% of clozapine-treated patients of European ancestry and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClozapineAntipsychotic AgentsHumansMaleAdultSchizophreniaSmoking

Stichwörter der Autor:innen

Asian continental ancestry groupCYP1A2Clozapine/bloodClozapine/metabolismClozapine/therapeutic useSmoking

Substanzen

ClozapineAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zürich, Zürich, Switzerland; Division of Psychiatry Research, Northwell Health, The Zucker Hillside Hospital, New York, NY,…
  • Department of Psychiatry, Hacettepe University Faculty of Medicine, Ankara, Turkey. Electronic address: eanil@hacettepe.edu.tr.
  • The National Clinical Research Centre for Mental Disorders & Beijing Key Lab of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China; Advanced Innovation Center for Human Brain Protectio…
  • Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; School of Pharmaceuti…
  • Center for Psychopharmacology, Diakonhjemmet Hospital, PO Box 23 Vinderen, 0319 Oslo, Norway; Department of Pharmacy, University of Oslo, Oslo, Norway. Electronic address: espen.molden@farmasi.uio.no.
  • Department of Physiology, Los Andes University Medical School, Mérida, Venezuela; Medical School, Anáhuac University, Querétaro, Mexico; Neuroorigen, Querétaro, Mexico.

Zitieren

APA

Schoretsanitis, G., Anıl Yağcıoğlu, A. E., Ruan, C. J., Eap, C. B., Molden, E., Baptista, T., Clark, S. R., Fernandez-Egea, E., Kim, S. H., Lane, H. Y., Leung, J., Maroñas Amigo, O., Motuca, M., Olmos, I., Every-Palmer, S., Procyshyn, R. M., Rohde, C., Satish, S., Schulte, P. F. J., …, & de Leon, J. (2024). Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition. Schizophrenia Research. https://doi.org/10.1016/j.schres.2023.05.010

Vancouver

Schoretsanitis G, Anıl Yağcıoğlu AE, Ruan CJ, Eap CB, Molden E, Baptista T, et al. Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition. Schizophrenia Research. 2024. doi:10.1016/j.schres.2023.05.010

BibTeX
@article{Schoretsanitis2024,
  author = {Schoretsanitis, Georgios and Anıl Yağcıoğlu, A Elif and Ruan, Can-Jun and Eap, Chin B and Molden, Espen and Baptista, Trino and Clark, Scott R and Fernandez-Egea, Emilio and Kim, Se Hyun and Lane, Hsien-Yuan and Leung, Jonathan and Maroñas Amigo, Olalla and Motuca, Mariano and Olmos, Ismael and Every-Palmer, Susanna and Procyshyn, Ric M and Rohde, Christopher and Satish, Suhas and Schulte, Peter F J and Spina, Edoardo and Takeuchi, Hiroyoshi and Verdoux, Hélène and Correll, Christoph U and de Leon, Jose},
  title = {Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition},
  journal = {Schizophrenia Research},
  year = {2024},
  doi = {10.1016/j.schres.2023.05.010}
}
Kostenlos starten →